The levels of both IgM and IgG antibodies in serums of the patients with critical COVID-19 were found to be lower than those of the patients with moderate and severe diseases; however, these were not significant (1.3 (0.4–6.0), 6.1 (1.9–9). This evidence concerns the gene CD40LG and COVID-19.